American Association for Cancer Research

June 4, 2025
By Marian (YoonJee) Chu
Epimab sells bispecific T-cell engager to Juri in $210M deal
Epimab Biotherapeutics Inc. licensed out a development-ready KLK2/CD3 bispecific T-cell engager (TCE) for advanced prostate cancer to Juri Biosciences Inc. through a potential $210 million deal.
June 3, 2025
By Marian (YoonJee) Chu
Epimab sells bispecific T-cell engager to Juri in $210M deal
Epimab Biotherapeutics Inc. licensed out a development-ready KLK2/CD3 bispecific T-cell engager (TCE) for advanced prostate cancer to Juri Biosciences Inc. through a potential $210 million deal.
May 28, 2025
By Marian (YoonJee) Chu
Epimab sells bispecific T-cell engager to Juri in $210M deal
Epimab Biotherapeutics Inc. licensed out a development-ready KLK2/CD3 bispecific T-cell engager (TCE) for advanced prostate cancer to Juri Biosciences Inc. through a potential $210 million deal.